Geer Eliza B
Departments of Medicine and Neurosurgery, Multidisciplinary Pituitary and Skull Base Tumor Center, Memorial Sloan Kettering Cancer Center, David H. Koch Center for Cancer Care, 530 East 74th Street, Box 19, New York, NY, 10021, USA.
Pituitary. 2023 Jun;26(3):303-306. doi: 10.1007/s11102-023-01320-9. Epub 2023 Apr 28.
Refractory pituitary adenomas are those that have progressed following standard of care treatments. Medical therapy options for these challenging tumors are limited.
To review the landscape of tumor directed medical therapies and off-label investigational approaches for refractory pituitary adenomas.
Literature on medical therapies for refractory adenomas was reviewed.
The established first-line medical therapy for refractory adenomas is temozolomide, which importantly may increase survival, but clinical trial data are still needed to clearly establish its efficacy, identify biomarkers of response, and clarify eligibility and outcome criteria. Other therapies for refractory tumors have only been described in case reports and small case series.
There are currently no approved non-endocrine medical therapies for refractory pituitary tumors. There is an urgent need for identifying effective medical therapies and studying them in multi-center clinical trials.
难治性垂体腺瘤是指在接受标准治疗后仍进展的肿瘤。针对这些具有挑战性的肿瘤的药物治疗选择有限。
综述难治性垂体腺瘤的肿瘤导向性药物治疗及非适应证研究方法。
回顾难治性腺瘤药物治疗的文献。
难治性腺瘤已确立的一线药物治疗是替莫唑胺，重要的是它可能提高生存率，但仍需要临床试验数据来明确确立其疗效、识别反应生物标志物并阐明适应证和结果标准。难治性肿瘤的其他治疗仅在病例报告和小病例系列中有所描述。
目前尚无批准用于难治性垂体肿瘤的非内分泌药物治疗。迫切需要确定有效的药物治疗并在多中心临床试验中进行研究。
